{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:44Z","timestamp":1791410804885,"version":"4.3.3"},"reference-count":183,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Historically, atherosclerotic cardiovascular disease (ASCVD) risk profile mitigation has had a predominant focus on low density lipoprotein cholesterol (LDL-C). In this narrative review we explore the residual ASCVD risk profile beyond LDL-C with a focus on hypertriglyceridaemia, recent clinical trials of therapeutics targeting hypertriglyceridaemia and novel modalities addressing other residual ASCVD risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Hypertriglyceridaemia remains a significant ASCVD risk despite low LDL-C in statin or proprotein convertase subtilisin\/kexin type 9 inhibitor-treated patients. Large population-based observational studies have consistently demonstrated an association between hypertriglyceridaemia with ASCVD. This relationship is complicated by the co-existence of low high-density lipoprotein cholesterol. Despite significantly improving atherogenic dyslipidaemia, the most recent clinical trial outcome has cast doubt on the utility of pharmacologically lowering triglyceride concentrations using fibrates. On the other hand, purified eicosapentaenoic acid (EPA), but not in combination with docosahexaenoic acid (DHA), has produced favourable ASCVD outcomes. The outcome of these trials suggests alternate pathways involved in ASCVD risk modulation. Several other pharmacotherapies have been proposed to address other ASCVD risk factors targeting inflammation, thrombotic and metabolic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>Hypertriglyceridaemia poses a significant residual ASCVD risk in patients already on LDL-C lowering therapy. Results from pharmacologically lowering triglyceride are conflicting. The role of fibrates and combination of EPA and DHA is under question but there is now convincing evidence of ASCVD risk reduction with pure EPA in a subgroup of patients with hypertriglyceridaemia. Clinical guidelines should be updated in line with recent clinical trials evidence. Novel agents targeting non-conventional ASCVD risks need further evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2024.1389106","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T01:04:11Z","timestamp":1722992651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape\u2014focus on hypertriglyceridaemia"],"prefix":"10.3389","volume":"11","author":[{"given":"Bilal","family":"Bashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Downie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"France","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison K.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhlaq","family":"Maan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Durrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"B1","article-title":"European Cardiovascular Disease Statistics 2017 [Internet]","year":"2017"},{"key":"B2","article-title":"Health Topics\u2014Heart Disease and Heart Attack [Internet]","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1201\/b13464","volume-title":"Hyperlipidaemia: Diagnosis and Management","author":"Durrington","year":"2007"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1093\/eurheartj\/ehv340","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"36","author":"Soran","year":"2015","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/MOL.0000000000000433","article-title":"Evidence for more intensive cholesterol lowering","volume":"28","author":"Soran","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e002765","DOI":"10.1161\/JAHA.115.002765","article-title":"Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson heart and Framingham offspring cohort studies","volume":"5","author":"Joshi","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1258\/acb.2011.010277","article-title":"Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients","volume":"48","author":"Soran","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/clinchem\/hvac213","article-title":"Diagnosis of familial dysbetalipoproteinemia based on the lipid abnormalities driven by APOE2\/E2 genotype","volume":"69","author":"Bea","year":"2023","journal-title":"Clin Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1161\/01.ATV.13.5.712","article-title":"Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment","volume":"13","author":"de Graaf","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"B30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0021-9150(98)00003-3","article-title":"Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia","volume":"138","author":"Durrington","year":"1998","journal-title":"Atherosclerosis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1365-2796.2006.01646.x","article-title":"Apolipoproteins AI and B as therapeutic targets","volume":"259","author":"Charlton-Menys","year":"2006","journal-title":"J Intern Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/heart.85.5.544","article-title":"An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia","volume":"85","author":"Durrington","year":"2001","journal-title":"Heart"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S0021-9150(98)00219-6","article-title":"Triglycerides are more important in atherosclerosis than epidemiology has suggested","author":"Durrington","year":"1998","journal-title":"Atherosclerosis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/1479164119828899","article-title":"The Reaven syndrome: an historical perspective","volume":"16","author":"Soran","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11886-020-01323-z","article-title":"Non-HDL cholesterol or apoB: which to prefer as a target for the prevention of atherosclerotic cardiovascular disease?","volume":"22","author":"Langlois","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.amjcard.2012.10.037","article-title":"Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome [from the limiting UNdertreatment of lipids in ACS with rosuvastatin (LUNAR) trial]","volume":"111","author":"Ballantyne","year":"2013","journal-title":"Am J Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12933-022-01525-5","article-title":"Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study","volume":"21","author":"Patel","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/metabo13050621","article-title":"Severe hypertriglyceridaemia and chylomicronaemia syndrome\u2014causes, clinical presentation, and therapeutic options","volume":"13","author":"Bashir","year":"2023","journal-title":"Metabolites"},{"key":"B39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1373\/clinchem.2010.157164","article-title":"Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58,434 individuals from the Copenhagen general population study","volume":"57","author":"Langsted","year":"2011","journal-title":"Clin Chem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1161\/01.CIR.100.7.723","article-title":"Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men","volume":"100","author":"Boquist","year":"1999","journal-title":"Circulation"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2337\/diacare.23.9.1401","article-title":"Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes","volume":"23","author":"Teno","year":"2000","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1373\/clinchem.2015.241752","article-title":"Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state","volume":"61","author":"White","year":"2015","journal-title":"Clin Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jamainternmed.2019.0392","article-title":"Association of nonfasting vs fasting lipid levels with risk of Major coronary events in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm","volume":"179","author":"Mora","year":"2019","journal-title":"JAMA Intern Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"B52","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/01.ATV.11.3.653","article-title":"Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease","volume":"11","author":"Groot","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1161\/01.ATV.15.11.1829","article-title":"Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women","volume":"15","author":"Ginsberg","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0021-9150(98)00184-1","article-title":"Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men","volume":"141","author":"Karpe","year":"1998","journal-title":"Atherosclerosis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12944-017-0625-0","article-title":"Hypertriglyceridemia and atherosclerosis","volume":"16","author":"Peng","year":"2017","journal-title":"Lipids Health Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1016\/j.jacc.2021.04.058","article-title":"Triglycerides and atherosclerosis: bringing the association into sharper focus","volume":"77","author":"Toth","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12929-017-0357-5","article-title":"Role of free fatty acids in endothelial dysfunction","volume":"24","author":"Ghosh","year":"2017","journal-title":"J Biomed Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020291","article-title":"Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications","volume":"10","author":"Kwaifa","year":"2020","journal-title":"Biomolecules"},{"key":"B59","first-page":"10","article-title":"Endothelial dysfunction in type 2 diabetes: targeting inflammation","author":"Sena","year":"2018"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1089\/ars.2013.5805","article-title":"Targeting the ubiquitin-proteasome system in atherosclerosis: status quo, challenges, and perspectives","volume":"21","author":"Wilck","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"B61","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fendo.2020.00504","article-title":"Hypertriglyceridemia and atherosclerosis: using human research to guide mechanistic studies in animal models","volume":"11","author":"Basu","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1515\/CCLM.2003.120","article-title":"Identification of lipoproteins of intestinal origin in human atherosclerotic plaque","volume":"41","author":"Pal","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cca.2007.12.012","article-title":"Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases","volume":"390","author":"Nakano","year":"2008","journal-title":"Clin Chim Acta"},{"key":"B64","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1001\/jama.2008.621","article-title":"Nonfasting triglycerides and risk of ischemic stroke in the general population","volume":"300","author":"Freiberg","year":"2008","journal-title":"JAMA"},{"key":"B66","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1161\/01.CIR.0000145542.24347.18","article-title":"Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-pacific region","volume":"110","author":"Patel","year":"2004","journal-title":"Circulation"},{"key":"B68","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00043798-200204000-00001","article-title":"Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik study","volume":"9","author":"J\u00f3nsd\u00f3ttir","year":"2002","journal-title":"J Cardiovasc Risk"},{"key":"B69","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"B70","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dom.13537","article-title":"Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol","volume":"21","author":"Nichols","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e015801","DOI":"10.1161\/JAHA.119.015801","article-title":"Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk Italian population: the TG-REAL retrospective cohort analysis","volume":"9","author":"Arca","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B72","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/2047487319898571","article-title":"Association of four lipid components with mortality, myocardial infarction, and stroke in statin-na\u00efve young adults: a nationwide cohort study","volume":"27","author":"Lee","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"B73","first-page":"374","article-title":"Relation of high plasma triglyceride levels associated with obesity and regional adipose tissue distribution to plasma lipoprotein-lipid composition in premenopausal women","volume":"12","author":"Despr\u00e9s","year":"1989","journal-title":"Clin Invest Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2015.06.057","article-title":"Relationship of the triglyceride to high-density lipoprotein cholesterol (TG\/HDL-C) ratio to the remainder of the lipid profile: the very large database of lipids-4 (VLDL-4) study","volume":"242","author":"Quispe","year":"2015","journal-title":"Atherosclerosis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.amjcard.2015.08.039","article-title":"Metabolic dyslipidemia and risk of coronary heart disease in 28,318 adults with diabetes Mellitus and low-density lipoprotein cholesterol <100\u2005mg\/dl","volume":"116","author":"Rana","year":"2015","journal-title":"Am J Cardiol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.04210.1126\/science.1161524","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science (1979)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1177\/2047487318796989","article-title":"Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy","volume":"25","author":"Tada","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","article-title":"Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial","volume":"4","author":"Murphy","year":"2019","journal-title":"JAMA Cardiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab","volume":"146","author":"Hagstr\u00f6m","year":"2022","journal-title":"Circulation"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/ATVBAHA.116.307601","article-title":"Non-HDL cholesterol and triglycerides","volume":"36","author":"Puri","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"B90","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate","volume":"40","year":"1978","journal-title":"Heart"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"B94","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"B95","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"Br Med J"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes Mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"N\u20133 fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified Omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"B105","doi-asserted-by":"publisher","first-page":"c6273","DOI":"10.1136\/bmj.c6273","article-title":"Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial","volume":"341","author":"Galan","year":"2010","journal-title":"Br Med J"},{"key":"B106","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"N\u20133 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamainternmed.2014.328","article-title":"Effect of long-chain \u03c9-3 fatty acids and lutein+zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial","volume":"174","year":"2014","journal-title":"JAMA Intern Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","article-title":"N\u20133 fatty acids in patients with multiple cardiovascular risk factors","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n\u22123 fatty acid supplements in diabetes mellitus","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n\u22123 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2018","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2018","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/jama.292.12.1440","article-title":"Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome","volume":"292","author":"Esposito","year":"2004","journal-title":"JAMA"},{"key":"B114","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12944-022-01747-2","article-title":"Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002\u20132012)","volume":"21","author":"Georgoulis","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.clnu.2016.01.018","article-title":"Energy-restricted, high-protein diets more effectively impact cardiometabolic profile in overweight and obese women than lower-protein diets","volume":"36","author":"Mateo-Gallego","year":"2017","journal-title":"Clin Nutr"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/eurjpc\/zwae003","article-title":"Omega-3 fatty acids for cardiovascular event lowering","volume":"31","author":"Kaur","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"B117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/B978-0-323-99991-5.00012-7","volume-title":"Cardiovascular Endocrinology & Metabolism Theory and Practice of Cardiometabolic Medicine","author":"Bashir","year":"2023"},{"key":"B118","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.atherosclerosis.2017.09.028","article-title":"Consumption of fish and vascular risk factors: a systematic review and meta-analysis of intervention studies","volume":"266","author":"Alhassan","year":"2017","journal-title":"Atherosclerosis"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3945\/ajcn.2009.27908","article-title":"Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham offspring cohort","volume":"90","author":"Rumawas","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e192224","DOI":"10.1001\/jamanetworkopen.2019.2224","article-title":"Assessment of the role of niacin in managing cardiovascular disease outcomes","volume":"2","author":"D\u2019Andrea","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B123","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression","volume":"37","author":"Schoonjans","year":"1996","journal-title":"J Lipid Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B125","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1365-2125.2012.04282.x","article-title":"The clofibrate saga: a retrospective commentary","volume":"74","author":"Oliver","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"B126","first-page":"939","article-title":"Therapeutic study of a synthetic hypocholesterolemic agent: phenyl-ethyl-acetic acid","volume":"62","author":"Cottet","year":"1954","journal-title":"Presse Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study. Implications for treatment","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"B129","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"B130","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1055\/s-0028-1109516","article-title":"Wirksamkeit und sicherheit von etofibrat bei patienten mit nicht proliferativer diabetischer retinopathie","volume":"226","author":"Emmerich","year":"2009","journal-title":"Klin Monbl Augenheilkd"},{"key":"B133","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"B134","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.therap.2017.07.002","article-title":"Fibrates et risques thrombo-emboliques veineux: \u00e9tude cas\/non-cas dans la base nationale de pharmacovigilance","volume":"72","author":"Humbert","year":"2017","journal-title":"Therapies"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/eurheartj\/ehp556","article-title":"Statins, fibrates, and venous thromboembolism: a meta-analysis","volume":"31","author":"Squizzato","year":"2010","journal-title":"Eur Heart J"},{"key":"B136","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.thromres.2012.08.296","article-title":"Lipid lowering drugs and the risk of recurrent venous thromboembolism","volume":"130","author":"Delluc","year":"2012","journal-title":"Thromb Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.thromres.2007.10.014","article-title":"Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?","volume":"122","author":"Lacut","year":"2008","journal-title":"Thromb Res"},{"key":"B138","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/eurjpc\/zwad331","article-title":"The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis","volume":"31","author":"Kim","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"962.e1","DOI":"10.1016\/j.amjmed.2009.03.030","article-title":"Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review","volume":"122","author":"Abourbih","year":"2009","journal-title":"Am J Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14227","article-title":"Managing hypertriglyceridemia for cardiovascular disease prevention: lessons from the PROMINENT trial","author":"Yamashita","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"B142","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/jdi.14013","article-title":"The influence of triglycerides on small dense low-density lipoprotein cholesterol levels is attenuated in low low-density lipoprotein-cholesterol range: implications for the negative results of the PROMINENT trial","volume":"14","author":"Hirano","year":"2023","journal-title":"J Diabetes Investig"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0140-6736(71)91658-8","article-title":"Plasma lipid and lipoprotein pattern in Greenlandic West-Coast Eskimos","volume":"297","author":"Bang","year":"1971","journal-title":"Lancet"},{"key":"B144","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow","year":"2015","journal-title":"Atherosclerosis"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.bpj.2021.04.009","article-title":"EPA And DHA differentially modulate membrane elasticity in the presence of cholesterol","volume":"120","author":"Jacobs","year":"2021","journal-title":"Biophys J"},{"key":"B146","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/FJC.0000000000000379","article-title":"Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents","volume":"68","author":"Mason","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.chemphyslip.2018.01.002","article-title":"Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by x-ray diffraction","volume":"212","author":"Sherratt","year":"2018","journal-title":"Chem Phys Lipids"},{"key":"B148","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1229130","article-title":"Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events","volume-title":"FrontCardiovasc Med","author":"Le","year":"2023"},{"key":"B149","article-title":"RESPECT-EPA: Highly Purified EPA Appears to Reduce Risks of CV Events in Japanese CAD Patients on Statins [Internet]","year":"2022"},{"key":"B150","article-title":"Randomized trial for evaluation in secondary prevention efficacy of combination therapy\u2013statin and eicosapentaenoic acid\u2014RESPECT-EPA","author":"Daida","year":""},{"key":"B151","article-title":"REDUCE-IT EPA Trial Shows Association Between Higher EPA Levels, Reduced CV Events [Internet]","year":"2020"},{"key":"B152","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2362.2008.02019.x","article-title":"Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome","volume":"38","author":"Chan","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"B153","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MOL.0000000000000889","article-title":"Established and potential cardiovascular risk factors in metabolic syndrome: effect of bariatric surgery","volume":"34","author":"Bashir","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/j.1550-8528.1999.tb00436.x","article-title":"Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study","volume":"7","author":"Sj\u00f6str\u00f6m","year":"1999","journal-title":"Obes Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa066254","article-title":"Effects of bariatric surgery on mortality in Swedish obese subjects","volume":"357","author":"Sj\u00f6str\u00f6m","year":"2007","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.amjmed.2016.02.004","article-title":"Changes in lipid profile of obese patients following contemporary bariatric surgery: a meta-analysis","volume":"129","author":"Heffron","year":"2016","journal-title":"Am J Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/1479164119826479","article-title":"Bariatric surgery as a model to explore the basis and consequences of the Reaven hypothesis: small, dense low-density lipoprotein and interleukin-6","volume":"16","author":"Adam","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41366-020-00727-9","article-title":"Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity","volume":"45","author":"Azmi","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"B161","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1210\/clinem\/dgac244","article-title":"Bariatric surgery-induced high-density lipoprotein functionality enhancement is associated with reduced inflammation","volume":"107","author":"Adam","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3389\/fimmu.2017.01512","article-title":"Effect of roux-en-Y bariatric surgery on lipoproteins, insulin resistance, and systemic and vascular inflammation in obesity and diabetes","volume":"8","author":"Yadav","year":"2017","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S2213-8587(16)30057-2","article-title":"Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study","volume":"4","author":"Brownrigg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"12573","DOI":"10.1038\/s41598-021-90346-9","article-title":"The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity","volume":"11","author":"Azmi","year":"2021","journal-title":"Sci Rep"},{"key":"B165","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/MOL.0000000000000770","article-title":"Lipids and peripheral neuropathy","volume":"32","author":"Iqbal","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11695-020-05052-8","article-title":"Improvements in diabetic neuropathy and nephropathy after bariatric surgery: a prospective cohort study","volume":"31","author":"Adam","year":"2021","journal-title":"Obes Surg"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s00125-023-05899-3","article-title":"The effect of surgical weight loss on diabetes complications in individuals with class II\/III obesity","volume":"66","author":"Reynolds","year":"2023","journal-title":"Diabetologia"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B170","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2018","journal-title":"N Engl J Med"},{"key":"B171","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B172","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ahj.2019.09.011","article-title":"The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics","volume":"218","author":"Nidorf","year":"2019","journal-title":"Am Heart J."},{"key":"B173","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2011","journal-title":"N Engl J Med"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-Term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"B177","article-title":"Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON) [Internet]","year":"2022"},{"key":"B178","article-title":"Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes (MultiSELECt) [Internet]","year":"2022"},{"key":"B179","article-title":"A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (KRAKEN) [Internet]","year":"2022"},{"key":"B180","article-title":"Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a))\u2014Outcomes Trial [Internet]","year":"2024"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"B182","article-title":"Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) [Internet]","year":"2022"},{"key":"B183","article-title":"Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL) [Internet]","year":"2024"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1389106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T01:04:19Z","timestamp":1722992659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1389106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":183,"alternative-id":["10.3389\/fcvm.2024.1389106"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1389106","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"article-number":"1389106"}}